No material insider signal. Monitor for any upcoming clinical trial readouts or partnership announcements that could move the stock; the selling is routine tax-related activity.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $16.81entry
- T+1 · 7mo ago +0.71%α +1.08% · $16.93
- T+5 · 6mo ago −1.73%α −4.08% · $16.52
- T+20 · 6mo ago +3.45%α −1.81% · $17.39
- T+60 · 4mo ago +40.39%α +38.91% · $23.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three NRIX insiders (CFO, CLO, CSO) sold a combined $231K in open-market sales, a trivial 0.014% of the company's $1.7B market cap. The selling is routine and does not signal insider concern, especially given the small dollar amounts relative to company size.
Key Financial Metrics
Key Facts
- Christine Ring (CLO) sold 8,148 shares at $16.96 for $138K on May 4.
- Hans van Houte (CFO) sold 2,388 shares at $16.65 for $40K on April 30.
- Gwenn Hansen (CSO) sold 3,214 shares at $16.65 for $53K on April 30.
- Total open-market sales: $231K; includes non-cash option exercises at $0.
- Sales represent 0.014% of NRIX's $1.7B market cap, immaterial.
Financial Impact
Total insider sales of $231K, insignificant relative to market cap.
Risk Factors
- Insider selling could increase if stock price rises further, but current levels are routine.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NRIX-1777932670171 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers